These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3315614)

  • 1. Consequences of antibody binding in vitro on the pharmacological properties of anisoylated plasminogen streptokinase activator complex.
    Fears R; Ferres H; Hibbs M; Standring R
    Drugs; 1987; 33 Suppl 3():64-8. PubMed ID: 3315614
    [No Abstract]   [Full Text] [Related]  

  • 2. Evidence for the progressive uptake of anisoylated plasminogen streptokinase activator complex by clots in human plasma in vitro.
    Fears R; Ferres H; Standring R
    Drugs; 1987; 33 Suppl 3():51-6. PubMed ID: 2960513
    [No Abstract]   [Full Text] [Related]  

  • 3. Evidence for a sustained fibrinolytic response to anisoylated plasminogen streptokinase activator complex in vitro.
    Fears R
    Drugs; 1987; 33 Suppl 3():83-7. PubMed ID: 3315617
    [No Abstract]   [Full Text] [Related]  

  • 4. The protective effect of acylation on the stability of anisoylated plasminogen streptokinase activator complex in human plasma.
    Fears R; Ferres H; Standring R
    Drugs; 1987; 33 Suppl 3():57-63. PubMed ID: 2960514
    [No Abstract]   [Full Text] [Related]  

  • 5. Streptokinase and anisoylated streptokinase plasminogen complex. Their action on haemostasis in human volunteers.
    Staniforth DH; Smith RA; Hibbs M
    Eur J Clin Pharmacol; 1983; 24(6):751-6. PubMed ID: 6350023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinase-plasminogen complex (BRL 26921).
    Matsuo O; Collen D; Verstraete M
    Thromb Res; 1981 Nov; 24(4):347-58. PubMed ID: 7038976
    [No Abstract]   [Full Text] [Related]  

  • 7. Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy.
    Crabbe SJ; Grimm AM; Hopkins LE
    Pharmacotherapy; 1990; 10(2):115-26. PubMed ID: 2140889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex.
    Ferres H
    Drugs; 1987; 33 Suppl 3():33-50. PubMed ID: 3315613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deacylation studies in vitro on anisoylated plasminogen streptokinase activator complex.
    Ferres H; Hibbs M; Smith RA
    Drugs; 1987; 33 Suppl 3():80-2. PubMed ID: 3315616
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effects of anistreplase on coronary patency in acute myocardial infarction].
    Pacouret G; Charbonnier B
    Arch Mal Coeur Vaiss; 1990 Feb; 83 Spec No 1():25-9. PubMed ID: 2108643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of anistreplase.
    Sherry S
    Clin Cardiol; 1990 Mar; Suppl 5():V3-10; discussion V27-32. PubMed ID: 2182238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anistreplase. Pharmacology and biological data].
    Samama M
    Arch Mal Coeur Vaiss; 1990 Feb; 83 Spec No 1():15-20. PubMed ID: 2108641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrin binding. An essential property of anisoylated plasminogen streptokinase activator complex.
    Banton CJ; Overell BG
    Drugs; 1987; 33 Suppl 3():93-6. PubMed ID: 2824169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of thrombolytic agents on infarct size and left ventricle systolic function in myocardial infarction].
    Bassand JP; Cassagnes J; Machecourt J; Anguenot T; Lusson JR; Borel E; Schiele F; Wolf JF; Vachet D
    Arch Mal Coeur Vaiss; 1990 Feb; 83 Spec No 1():31-6. PubMed ID: 2108644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic properties of anisoylated plasminogen streptokinase activator complex and other thrombolytic agents in animals and in humans.
    Nunn B; Esmail A; Fears R; Ferres H; Standring R
    Drugs; 1987; 33 Suppl 3():88-92. PubMed ID: 3315618
    [No Abstract]   [Full Text] [Related]  

  • 16. [T-PA and APSAC, new fibrinolytics].
    Med Monatsschr Pharm; 1986 Nov; 9(11):326-7. PubMed ID: 3100917
    [No Abstract]   [Full Text] [Related]  

  • 17. A comparison of acylated streptokinase-plasminogen complex and streptokinase in healthy volunteers.
    Prowse CV; Hornsey V; Ruckley CV; Boulton FE
    Thromb Haemost; 1982 Apr; 47(2):132-5. PubMed ID: 7048621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction.
    Monk JP; Heel RC
    Drugs; 1987 Jul; 34(1):25-49. PubMed ID: 3308411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An anti-plasminogen antibody preparation that inhibits the activation of human plasminogen but enhances the activator activity of the B-chain-streptokinase complex.
    Summaria L; Pavlovic B; Sandesara J
    Thromb Res; 1989 Apr; 54(1):1-15. PubMed ID: 2727955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet aggregation by IgG anti-streptokinase and anisoylated plasminogen-streptokinase activator complex: heterogenous responses in platelet-rich plasma but not in washed platelets.
    Abdelouahed M; Elalamy I; Samama MM; Hatmi M
    Thromb Res; 1997 May; 86(3):255-62. PubMed ID: 9175246
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.